Nanoliposomal irinotecan in patients with pancreatic cancer - overall survival and results of patients treated according to the protocol in the NAPOLI-1 study
Abstract
The prognosis of patients with advanced pancreatic adenocarcinoma is still quite unfavorable, unfortunately the gradual improvement of treatment results in other malignancies does not copy this malignancy. Within the 1st palliative treatment line, the triplet regimen FOLFIRINOX or the dual combination nab-paclitaxel + gemcitabine is used, or in patients with poor performance status gemcitabine in monotherapy.
The higher lines of treatment for this malignancy are not clearly defined - gemcitabine is the most commonly used monotherapy in previous FOLFIRINOX regimens, mostly with very low treatment benefits. In the case of first-line treatment with gemcitabine with / without nab-paclitaxel, there are limited data on the efficacy of the fluoropyrimidine monotherapy regimen or FOLFOX or FOLFIRI in the 2nd line.